(Bloomberg) -- Seventy coronavirus vaccines are in development, with three being tested in human trials, the World Health Organization said. The outbreak has stabilized across the U.S., according to the head of the Centers for Disease Control and Prevention.New York state passed 10,000 deaths over the weekend, plateauing as the daily number fell below 700, Governor Andrew Cuomo said. Mayor Bill de Blasio of New York City, the epicenter of the U.S. outbreak, said it could be summer or fall before the city can start returning to normal.U.S. stocks fell, while markets across Europe were closed for the Easter holiday.Key DevelopmentsCoronavirus Tracker: Global cases reach 1.88 million; deaths top 117,00070 coronavirus vaccines in development globallySpain reports smallest number of new infections since March 20Fauci says U.S. reopening could start ‘in some ways’ in MayCruise passengers spend Easter on ‘ghost ship’The Virus Should Wake Up the West: Micklethwait and WooldridgeFrench Deaths Rise...
Square, the bitcoin-friendly company behind Cash App, announced Monday it is participating in the U.S. government’s emergency Paycheck Protection Program....
And just like that, Novavax (NVAX) is back in the spotlight. Gaining a whopping 328% since the start of 2020, the healthcare company has consistently attracted attention from market watchers, primarily thanks to its efforts to develop a vaccine against COVID-19. The latest reason for its appearance on Wall Street’s radar? Its vaccine development program’s giant leap forward.On April 8, the company announced that it had identified a lead COVID-19 vaccine candidate. The experimental vaccine, NVX-CoV2373, is a prefusion protein created using NVAX's patented lipid nanoparticle platform, with a Phase 1 first-in-human study set to begin in mid-May. As a result of this rapid timeline, NVAX could release early safety and immunogenicity data as soon as July based on the expected 35-day trial schedule.It should be noted that according to preclinical data, NVX-CoV2373 was able to produce high titer neutralizing antibodies against SARS-CoV-2 virus after a single immunization, with the result...
And just like that, Novavax (NVAX) is back in the spotlight. Gaining a whopping 328% since the start of 2020, the healthcare company has consistently attracted attention from market watchers, primarily thanks to its efforts to develop a vaccine against COVID-19. The latest reason for its appearance on Wall Street’s radar? Its vaccine development program’s giant leap forward.On April 8, the company announced that it had identified a lead COVID-19 vaccine candidate. The experimental vaccine, NVX-CoV2373, is a prefusion protein created using NVAX's patented lipid nanoparticle platform, with a Phase 1 first-in-human study set to begin in mid-May. As a result of this rapid timeline, NVAX could release early safety and immunogenicity data as soon as July based on the expected 35-day trial schedule.It should be noted that according to preclinical data, NVX-CoV2373 was able to produce high titer neutralizing antibodies against SARS-CoV-2 virus after a single immunization, with the result...
(Bloomberg) -- Seventy coronavirus vaccines are in development, with three being tested in human trials, the World Health Organization said. The outbreak has stabilized across the U.S., according to the head of the Centers for Disease Control and Prevention.New York state passed 10,000 deaths over the weekend, plateauing as the daily number fell below 700, Governor Andrew Cuomo said. Mayor Bill de Blasio of New York City, the epicenter of the U.S. outbreak, said it could be summer or fall before the city can start returning to normal.U.S. stocks fell, while markets across Europe were closed for the Easter holiday.Key DevelopmentsCoronavirus Tracker: Global cases reach 1.87 million; deaths top 116,00070 coronavirus vaccines in development globallySpain reports smallest number of new infections since March 20Fauci says U.S. reopening could start ‘in some ways’ in MayCruise passengers spend Easter on ‘ghost ship’The Virus Should Wake Up the West: Micklethwait and WooldridgeGreek PM Sees...
